UPDATE: Denali Therapeutics Q3 Adj. EPS $(0.64) Misses $(0.53) Estimate, Sales $17.778M Beat $10.657M Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings BeatsEarnings Misses
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.53) by 20.75 percent. This is a 13.51 percent increase over losses of $(0.74) per share
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.53) by 20.75 percent. This is a 13.51 percent increase over losses of $(0.74) per share from the same period last year. The company reported quarterly sales of $17.778 million which beat the analyst consensus estimate of $10.657 million by 66.83 percent.